Evommune (EVMN)
Develops chronic-inflammation therapies centered on EVO756 and EVO301 clinical programs.
Something off on this page? Send us feedback.
Advances two chronic-inflammation drug candidates: EVO756 for MRGPRX2 biology and EVO301 for the IL-18 pathway. After a June 2026 CSU trial miss, EVO756 work continues in atopic dermatitis and migraine while EVO301 moves toward a later AD study.
Develops therapies for chronic inflammatory diseases through a small clinical pipeline rather than marketed products. EVO756 is an oral small-molecule antagonist of MRGPRX2, and EVO301 is a long-acting injectable fusion protein aimed at the IL-18 inflammatory pathway.
Operates from Palo Alto as one company-wide segment, with resources allocated across functions and research programs. The team is rooted in Dermira, and founder Luis Pena remains chief executive.
Current execution is defined by pipeline triage after the June 2026 EVO756 CSU study missed its main endpoint. EVO756 development continues in atopic dermatitis and migraine, while EVO301 is advancing in atopic dermatitis after positive proof-of-concept data. The business depends on clinical readouts and licensing relationships before product sales.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 9, 2026 | Stifel Nicolaus | Target | Target: — | Target: $30 |
| Sep 9, 2026 | Raymond James | Target | Target: $40 | Target: $18 |
| Sep 9, 2026 | Leerink Partners | Reiterate | Rating: —Target: $42 | Target: $22 |
| Sep 9, 2026 | RBC Capital | Reiterate | Rating: —Target: — | Target: $21 |
| Aug 26, 2026 | Needham | Initiate | Rating: — |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $200.8M · Total debt $8.1M · Total assets $301.9M · Shareholders' equity $277.6M
- Revenue
- $0
- Operating income
- −$34.9M
- Net income
- −$32.2M
No dividends on record.
| Institutions | 0.11% | 39.0K shares | |
|---|---|---|---|
| 1 holder · as of Jun 30, 2026 | |||
| Other | 99.89% | 36.25M shares | |
| remainder | |||
36.29M company shares as of Sep 1, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (64.92M in the company's Sep 23, 2026 report, 36.29M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Guardian Partners Inc.Institution | 0.11% | 38,972 | as of Jun 30, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
- AbbVie
Broad AD, UC, and migraine overlap through RINVOQ, SKYRIZI, QULIPTA
- Eli Lilly
AD, UC, and migraine biologics overlap through EBGLYSS, Omvoh, Emgality
- Regeneron
Type-2 biologic leader in AD and CSU through Dupixent
- Pfizer
Oral AD, UC, and migraine overlap through CIBINQO, VELSIPITY, Nurtec
- Novartis (ADR)
CSU-focused oral BTK competition through Rhapsido
- Celldex Therapeutics
Clinical mast-cell competitor in CSU through barzolvolimab
- Johnson & Johnson
UC cytokine incumbent through TREMFYA's IL-23 franchise
- Jasper Therapeutics
Smaller KIT-directed mast-cell challenger in CSU and CIndU
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Evommune | $9.70 | +1.15% | $343.0M | — | — | 34.3 | — |
| AbbVie | $265.01 | −0.10% | $467.37B | 74.5 | 17.5 | 7.3 | +10.2% |
| Eli Lilly | $1,170.23 | −0.02% | $1.10T | 39.1 | 28.6 | 13.8 | +47.7% |
| Regeneron | $805.00 | +0.11% | $82.23B | 19.7 | 13.3 | 5.3 | +16.7% |
| Pfizer | $27.90 | −0.11% | $158.10B | 36.7 | 10.0 | 2.5 | +2.6% |
| Novartis (ADR) | $141.28 | +0.01% | $267.96B | 21.3 | 15.0 | 4.8 | +0.9% |
| Celldex Therapeutics | $33.78 | +0.78% | $2.52B | — | — | 22,510.2 | −97.0% |
| Johnson & Johnson | $266.97 | −0.86% | $649.40B | 31.2 | 22.7 | 6.6 | +6.6% |
| Jasper Therapeutics | $0.6353 | +0.65% | $9.8M | — | — | — | — |
| Median | 33.9 | 16.2 | 6.6 | +6.6% |